It is a psilocin-based compound being investigated for therapeutic use in Binge Eating Disorder.

Where is the clinical trial being conducted?

The trial is conducted in partnership with Swinburne University in a regulated clinical environment.

What is the primary goal of the study?

The trial aims to assess the safety and impact of intravenous psilocin therapy.

Tryptamine Therapeutics advances psilocin study for Binge Eating Disorder Asx 300

3 min read | August 07, 2025 05:08 PM AEST | By Team Kalkine Media

Google News:

Tryptamine Therapeutics advances psilocin study for Binge Eating Disorder Asx 300 — Image source: Shutterstock

Permit Secures Clinical Trial Logistics

With the formal permit in place, Tryptamine Therapeutics Ltd (ASX:TYP) is now set to initiate supply of its psilocin compound TRP-8803 to Swinburne University. Preparations for batch deliveries are underway, positioning the research team to commence dosing activities within the current quarter. The study aims to assess the treatment's relevance for individuals diagnosed with Binge Eating Disorder in a monitored clinical setting.

Study Structure and Initial Enrolments

Patient screening has already begun, with several individuals completing the initial application process. These candidates are expected to undergo in-person interviews shortly, paving the way for formal enrolment and baseline assessments. The clinical trial will consist of two groups, each receiving two sessions of TRP-8803 spaced by a fortnight. Participants will receive therapeutic support alongside dosing sessions.

Focus on Safety and Response Evaluation

The primary aim of the trial is to assess the safety profile of repeated TRP-8803 exposure. Monitoring will continue for several weeks following the final administration. In addition to safety assessments, the study will explore indicators such as changes in behavioural patterns related to Binge Eating Disorder and shifts in associated health markers. The therapy sessions will be coupled with integration support to enhance psychological outcomes.

Strategic Direction for Future Applications

asx200 aligned biotech research continues to evolve, with Tryptamine Therapeutics Ltd examining broader implications of psilocin-based therapy. Data collected from this open-label study will also be used to investigate secondary conditions that often accompany Binge Eating Disorder. These insights may influence future therapeutic approaches and compound development within the clinical pipeline.

Collaborative Research with Swinburne

The study is being conducted in partnership with Swinburne University, which is recognised for its contributions to mental health research. The collaboration supports evidence-based exploration of psychedelic compounds in controlled therapeutic settings. The secured permit from health authorities has enabled access to regulated substances, allowing the research team to focus on delivering scientifically grounded insights into treatment efficacy.

Frequently Asked Questions

What is TRP-8803?
It is a psilocin-based compound being investigated for therapeutic use in Binge Eating Disorder.
Where is the clinical trial being conducted?
The trial is conducted in partnership with Swinburne University in a regulated clinical environment.
What is the primary goal of the study?
The trial aims to assess the safety and impact of intravenous psilocin therapy.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.